Johnson & Johnson announced new Phase 2 data for nipocalimab, an immunoselective FcRn blocker, showing greater clinical response in Sjögren's disease patients with elevated autoantibodies and IgG levels. The drug reduced disease activity and symptoms like dryness, fatigue, and pain, particularly in patients with more severe disease. These findings support ongoing Phase 3 trials and highlight nipocalimab's potential as a targeted treatment preserving immune function. The data were presented at the 2026 EULAR Congress.
Johnson & Johnson's nipocalimab, a novel FcRn blocker, met its primary endpoint by significantly reducing disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) at 24 weeks, with benefits sustained through 52 weeks in a...
Nanobiotix completed a €86.1 million follow-on offering in May 2026 to accelerate development of its nanotherapeutic platforms. New data from its Phase 2 study of JNJ-1900 (NBTXR3) in Stage 3 inoperable non-small cell lung cancer showed promising res...
Legend Biotech, a leader in cell therapy, reported that its CAR-T treatment CARVYKTI generated nearly $2 billion in sales in 2025. CARVYKTI, developed and co-promoted with Johnson & Johnson, is a one-time infusion therapy for multiple myeloma and has...
Johnson & Johnson's Phase 3 PROTEUS study shows ERLEADA (apalutamide) combined with hormone therapy before and after surgery significantly improves outcomes for high-risk localized prostate cancer patients. The treatment increased the chance of minim...
Johnson & Johnson reported that subcutaneous amivantamab, a dual EGFR and MET inhibitor, achieved a 42% overall response rate in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. More...
